Business context and reporting period
Entity note: The supplied filing is for Novus Therapeutics, Inc. (Nasdaq: NVUS), not Eledon Pharmaceuticals, Inc. It is a Form 10-Q for the quarter ended September 30, 2019, filed November 12, 2019.
Novus is a pre-revenue specialty pharmaceutical company developing treatments for ear, nose and throat disorders. Its lead candidate, OP0201, is a nasal aerosol drug-device product for otitis media; an exploratory Phase 2a study in infants and children was ongoing. The company reported no product sales and had no approved products. Its foam-based program was not being advanced while resources were focused on OP0201.
Financial performance and liquidity
Amounts below are in millions of dollars unless otherwise stated. The filing reports no revenue; operating margins are therefore not meaningful.
| Metric | Q3 2019 | Q3 2018 | Nine months 2019 | Nine months 2018 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development expense | $1.509 | $1.651 | $6.795 | $4.077 |
| General and administrative expense | $1.411 | $1.848 | $5.089 | $5.406 |
| Total operating expenses | $2.920 | $3.499 | $11.884 | $9.483 |
| Net loss | $2.893 | $3.496 | $11.867 | $9.491 |
| Loss per share, basic and diluted | $0.22 | $0.37 | $1.04 | $1.07 |
At September 30, 2019, cash was $10.814 million, working capital was $10.6 million, total assets were $15.218 million, and total liabilities were $1.852 million. There was no reported conventional debt; liabilities included $0.368 million of operating lease obligations. Accumulated deficit was $53.438 million.
Cash used in operating activities was $11.834 million for the first nine months, versus $8.540 million a year earlier. Financing provided $9.676 million, principally from the 2019 equity offering; cash declined $2.158 million to $10.814 million. The company stated that cash was insufficient to fund operations for 12 months from financial-statement issuance and disclosed substantial doubt about its ability to continue as a going concern.
Material changes versus the prior comparable period
- Q3 operating expenses fell 17% and net loss narrowed 17%, mainly from lower R&D and G&A costs.
- For the first nine months, operating expenses rose 25% and net loss widened 25%. R&D increased 67%, primarily because OP0201 clinical costs rose $2.4 million; G&A declined 6%.
- Operating cash use increased by $3.294 million year over year. The company raised approximately $10.7 million gross in a registered direct offering in May 2019, issuing 3,449,112 shares alongside warrants, and reported $9.676 million of net financing cash for the nine-month period.
- Common shares outstanding increased from 9.422 million at December 31, 2018 to 12.975 million at September 30, 2019. Potential warrant and other share dilution is also relevant.
Outlook, risks, contingencies and unusual items
- Management expected continued losses and negative operating cash flows and said additional financing would be needed. It stated that existing cash was expected to fund the ongoing OP0201 Phase 2a study, but not subsequent studies or commercialization. Financing may not be available on acceptable terms; cost reductions, delays or curtailment of R&D, or other actions could be required.
- The company said it was implementing cost cuts and referred to preserving asset value as it sought strategic alternatives. No specific outcome or financial benefit from alternatives was provided.
- Nasdaq notified the company in August 2019 that it failed the $1.00 minimum bid-price requirement. The stated deadline to regain compliance was February 4, 2020; delisting could impair trading and future fundraising.
- Key operating risks include clinical efficacy and safety, trial enrollment and timing, regulatory approval, scaling up manufacturing, reliance on sole suppliers, and the need for external financing. No assurance was given that OP0201 would succeed or be approved.
- Tokai-related securities litigation remained outstanding: a class-certification motion was pending in the Jackie888 action, and the Angelos motion-to-dismiss hearing had been continued. The filing said outcomes and reasonably possible losses could not be estimated; no litigation liability was accrued. The Wu action had been dismissed with prejudice.
- Potential Israeli Innovation Authority grant repayments of approximately $0.537 million are contingent on successful development and sales; no liability was recorded because the company had not generated sales. OP0201 license terms also include potential development, regulatory and sales milestones and royalties; a $0.300 million milestone was paid in March 2019.
- Management reported disclosure controls effective as of September 30, 2019 and no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Confirm the intended issuer: this filing is Novus Therapeutics, not Eledon Pharmaceuticals.
- Review the going-concern disclosure, cash runway assumptions, planned financing needs and any subsequent financing or cost-reduction actions.
- Check OP0201 Phase 2a progress, data, enrollment and plans for further trials, alongside the cash required to advance the program.
- Assess the potential dilution and warrant terms associated with the 2019 equity offering, as well as future capital-raising capacity.
- Verify Nasdaq bid-price compliance developments and the status and potential exposure of the outstanding litigation.